Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target
Morgan Stanley has maintained its 'Hold' rating on Recursion Pharmaceuticals (RXRX) while adjusting its price target to $5.60.
Stocks · News reference
J.P. Morgan analyst Priyanka Grover has maintained a "Buy" rating on Recursion Pharmaceuticals, setting a price target of $7.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Morgan Stanley has maintained its 'Hold' rating on Recursion Pharmaceuticals (RXRX) while adjusting its price target to $5.60.
Recursion Pharmaceuticals has reached an agreement with the FDA on the design of its registrational Phase 3 clinical trial for REC-4881, an investigational oral MEK1/2 inhibitor for treating familial adenomatous polyposis (FAP).
Bank of America Merrill Lynch has issued a neutral rating on Recursion Pharmaceuticals with a price target of $6.00.
Recursion Publishing has signed Dr. Renata Moon for the upcoming release of her book, 'White Coats, Red Flags'.
The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.